866-997-4948(US-Canada Toll Free)

Investigation Report on China Ranibizumab Market, 2012-2019

Published By :

China Research and Intelligence Co., Ltd. (CRI)

Published Date : Jul 2015

Category :

Therapeutic Area

No. of Pages : 20 Pages


As macular is the area responsible for high-resolution vision near the center of the retina, macular degeneration, once occurred, will lead to a loss of central vision and distorted vision in the form of metamorphopsia or even irreversible blindness. According to a report published by WHO in 2012, 30 million people suffer from macular degeneration globally, among which about 500,000 end up in blindness per year. In the US, blindness cases caused by macular degeneration outnumbers those caused by glaucoma, cataract and diabetic retinopathy. According to a Chinese investigation in 2012, the incidence of macular degeneration reaches up to 15.5% among old people aged above 50 and 20.2% among those aged above 70. With ageing population, the incidence of macular degeneration will continue to go up.

Developed by Novartis, ranibizumab was approved by CFDA to treat wet age-related macular degeneration (AMD) in 2012. Currently, only Lucentis, a product of Novartis, is available in the Chinese market. However, in Dec. 2013, as the first self-developed drug for the treatment of wet AMD in China, conbercept ophthalmic injection got CFDA’s approval.

Ranibizumab develops fast after entering China, sales value in 19 sample hospitals in key cities in 2014 reaching CNY 245 million with a year-on-year growth of 26.29% and CAGR during the last three years reaching 200%. With ageing population, the incidence of macular degeneration goes up gradually. Hence the vast demand for ranibizumab in China. Currently, ranibizumab injections in mainland China all come from Novatis. But as conbercept ophthalmic injection is proved by the clinical studies to improve vision better with a lower administration frequency, it is expected to break the monopoly of Novatis in the wet AMD drug market in the next few years.

Readers can get at least the following information from this report:
  • market size of ranibizumab in China
  • competitive landscape of ranibizumab in Chinese market
  • price of ranibizumab made by different enterprises in China
  • market outlook of ranibizumab in China
The author suggests the following groups of people purchase this report:
  • manufacturers of monoclonal antibody
  • manufacturers of ophthalmic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

1 Related Concepts of Ranibizumab
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Ranibizumab in China
2.1 Patent Status and Approval Information of Ranibizumab in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Ranibizumab in China, 2012-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Ranibizumab in China, 2012-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Ranibizumab in China, 2012-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Ranibizumab in Chinese Hospitals in 2014

7 Major Manufacturers of Ranibizumab in Chinese Market, 2012-2014

8 Market Outlook of Ranibizumab in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

List of Chart


Chart Patent Status of Ranibizumab in China
Chart Registration Information of Ranibizumab in China
Chart Sales Status of Ranibizumab in China
Chart Sales Value of Ranibizumab in China, 2012-2014
Chart Sales Value of Ranibizumab in Some Regions in China, 2012-2014
Chart Sales Volume of Ranibizumab in China, 2012-2014
Chart Sales Volume of Ranibizumab in Some Regions in China, 2012-2014
Chart Price of Ranibizumab Made by Novartis in Some Chinese Cities in 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *